Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
"Sam Conaway's proven track record in the successful launch of novel products and therapeutic procedures is a critical addition to our Board of Directors at this juncture," said Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health.
- "Sam Conaway's proven track record in the successful launch of novel products and therapeutic procedures is a critical addition to our Board of Directors at this juncture," said Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health.
- Sales in the Cardiology Group at Boston Scientific Corporation and as Chairman of Close the Gap, the Boston Scientific Health Equity initiative.
- "I am deeply honored and excited to join the Board of Directors at Fractyl Health, a company at the cutting edge of addressing some of the most pressing healthcare challenges of our time," said Mr. Conaway.
- Mr. Conaway's expertise is expected to play a key role in Fractyl Health's ongoing efforts to complete its pivotal clinical studies in T2D and weight loss maintenance.